Page last updated: 2024-11-06

aspartate-beta-hydroxamate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

beta-aspartylhydroxamic acid: RN given refers to (DL)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID65274
CHEMBL ID216856
SCHEMBL ID9684668
MeSH IDM0083505

Synonyms (18)

Synonym
nsc141662
nsc-141662
20154-32-9
nsc-528507
nsc528507
DAH ,
aspartic acid beta-hydroxamate
beta-aspartylhydroxamate
dl-asparagine, n-hydroxy-
nsc 528507
aspartate-beta-hydroxamate
d-aspartic acid beta-hydroxamate
beta-aspartylhydroxamic acid
CHEMBL216856
2-amino-4-(hydroxyamino)-4-oxobutanoic acid
SCHEMBL9684668
ZBYVTTSIVDYQSO-UHFFFAOYSA-N
3-alaninehydroxamic acid
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (20)

Assay IDTitleYearJournalArticle
AID553520Drug uptake in Saccharomyces cerevisiae ADCDR2 expressing Candida albicans CDR2 efflux pump at 200 uM pretreated for 10 mins measured after 60 mins by fluorescamine staining2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Enhanced susceptibility to antifungal oligopeptides in yeast strains overexpressing ABC multidrug efflux pumps.
AID553852Antifungal activity against wild type Candida albicans 10261 in RPMI-1640 buffered medium after 24 hrs by microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Enhanced susceptibility to antifungal oligopeptides in yeast strains overexpressing ABC multidrug efflux pumps.
AID553849Antifungal activity against Saccharomyces cerevisiae ADCDR1 expressing Candida albicans CDR1 efflux pump in YNPG medium containing 1 mg/ml 1-glutamate after 24 hrs by microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Enhanced susceptibility to antifungal oligopeptides in yeast strains overexpressing ABC multidrug efflux pumps.
AID553853Antifungal activity against fluconazole sensitive Candida albicans isolate Gu4 in RPMI-1640 buffered medium after 24 hrs by microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Enhanced susceptibility to antifungal oligopeptides in yeast strains overexpressing ABC multidrug efflux pumps.
AID1135958Inhibition of asparagine synthetase in human KB cells at 1 mM1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Potential inhibitors of L-asparagine biosynthesis. 4. Substituted sulfonamide and sulfonylhydrazide analogues of L-asparagine.
AID553518Drug uptake in Saccharomyces cerevisiae ADCDR1 expressing Candida albicans CDR1 efflux pump at 200 uM pretreated for 10 mins measured after 60 mins by fluorescamine staining2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Enhanced susceptibility to antifungal oligopeptides in yeast strains overexpressing ABC multidrug efflux pumps.
AID553854Antifungal activity against fluconazole resistant Candida albicans isolate Gu5 overexpressing CDR1 and CDR2 in RPMI-1640 buffered medium after 24 hrs by microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Enhanced susceptibility to antifungal oligopeptides in yeast strains overexpressing ABC multidrug efflux pumps.
AID553851Antifungal activity against Saccharomyces cerevisiae ADMDR1 expressing Candida albicans MDR1 efflux pump in YNPG medium containing 1 mg/ml 1-glutamate after 24 hrs by microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Enhanced susceptibility to antifungal oligopeptides in yeast strains overexpressing ABC multidrug efflux pumps.
AID274639Inhibition of CSK at 25 uM in presence of 12 mM MgCl22006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Design and evaluation of hydroxamate derivatives as metal-mediated inhibitors of a protein tyrosine kinase.
AID553516Drug uptake in Saccharomyces cerevisiae AD12345678 at 200 uM pretreated for 10 mins measured after 60 mins by fluorescamine staining2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Enhanced susceptibility to antifungal oligopeptides in yeast strains overexpressing ABC multidrug efflux pumps.
AID553856Antifungal activity against fluconazole resistant Candida albicans isolate B4 overexpressing MDR1 in RPMI-1640 buffered medium after 24 hrs by microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Enhanced susceptibility to antifungal oligopeptides in yeast strains overexpressing ABC multidrug efflux pumps.
AID553848Antifungal activity against Saccharomyces cerevisiae AD12345678 in YNPG medium containing 1 mg/ml 1-glutamate after 24 hrs by microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Enhanced susceptibility to antifungal oligopeptides in yeast strains overexpressing ABC multidrug efflux pumps.
AID553850Antifungal activity against Saccharomyces cerevisiae ADCDR2 expressing Candida albicans CDR2 efflux pump in YNPG medium containing 1 mg/ml 1-glutamate after 24 hrs by microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Enhanced susceptibility to antifungal oligopeptides in yeast strains overexpressing ABC multidrug efflux pumps.
AID274640Inhibition of CSK at 25 uM in presence of 12 mM MgCl2 and 0.2 mM CoCl22006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Design and evaluation of hydroxamate derivatives as metal-mediated inhibitors of a protein tyrosine kinase.
AID553847Antifungal activity against wild type Saccharomyces cerevisiae ATCC 9763 in YNPG medium containing 1 mg/ml 1-glutamate after 24 hrs by microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Enhanced susceptibility to antifungal oligopeptides in yeast strains overexpressing ABC multidrug efflux pumps.
AID553535Drug accumulation in Saccharomyces cerevisiae ADCDR1 expressing Candida albicans CDR1 efflux pump reenergized with glucose at pH 6.0 assessed as intracellular accumulation after 60 mins by fluorescamine staining2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Enhanced susceptibility to antifungal oligopeptides in yeast strains overexpressing ABC multidrug efflux pumps.
AID553536Drug accumulation in Saccharomyces cerevisiae ADCDR2 expressing Candida albicans CDR2 efflux pump reenergized with glucose at pH 6.0 after 60 mins by fluorescamine staining2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Enhanced susceptibility to antifungal oligopeptides in yeast strains overexpressing ABC multidrug efflux pumps.
AID553855Antifungal activity against fluconazole sensitive Candida albicans isolate B3 in RPMI-1640 buffered medium after 24 hrs by microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Enhanced susceptibility to antifungal oligopeptides in yeast strains overexpressing ABC multidrug efflux pumps.
AID553534Drug accumulation in Saccharomyces cerevisiae AD12345678 reenergized with glucose at pH 6.0 assessed as intracellular accumulation after 60 mins by fluorescamine staining2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Enhanced susceptibility to antifungal oligopeptides in yeast strains overexpressing ABC multidrug efflux pumps.
AID553522Drug uptake in Saccharomyces cerevisiae ADMDR1 expressing Candida albicans MDR1 efflux pump at 200 uM pretreated for 10 mins measured after 60 mins by fluorescamine staining2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Enhanced susceptibility to antifungal oligopeptides in yeast strains overexpressing ABC multidrug efflux pumps.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (38)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (13.16)18.7374
1990's18 (47.37)18.2507
2000's9 (23.68)29.6817
2010's6 (15.79)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.08

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.08 (24.57)
Research Supply Index3.66 (2.92)
Research Growth Index4.75 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.08)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other38 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]